Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Transcenta Starts US Trials of Gremlin1 mAb for Prostate and Colorectal Cancer

publication date: Mar 23, 2023

Suzhou Transcenta Holding has started a US Phase trial of TST00, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1 in patients with solid tumors. Gremlin1, a member of the TGF-β superfamily, is a highly conserved secreted protein that is thought to play important roles in several solid tumor cancers. Transcenta says TST003 has shown promising single agent and combination activity in xenograft tumor models from difficult-to-treat solid tumors resistant to checkpoint inhibitors including castration resistant prostate cancer and microsatellite stable colorectal cancer. Transcenta started a similar China trial earlier this year. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital